Literature DB >> 21640469

Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction.

Douglas J Martin1, Marina Ramirez-Alvarado.   

Abstract

Amyloid formation occurs when a precursor protein misfolds and aggregates, forming a fibril nucleus that serves as a template for fibril growth. Glycosaminoglycans are highly charged polymers known to associate with tissue amyloid deposits that have been shown to accelerate amyloidogenesis in vitro. We studied two immunoglobulin light chain variable domains from light chain amyloidosis patients with 90% sequence identity, analyzing their fibril formation kinetics and binding properties with different glycosaminoglycan molecules. We find that the less amyloidogenic of the proteins shows a weak dependence on glycosaminoglycan size and charge, while the more amyloidogenic protein responds only minimally to changes in the glycosaminoglycan. These glycosaminoglycan effects on fibril formation do not depend on a stable interaction between the two species but still show characteristic traits of an interaction-dependent mechanism. We propose that transient, predominantly electrostatic interactions between glycosaminoglycans and the precursor proteins mediate the acceleration of fibril formation in vitro.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21640469      PMCID: PMC3133826          DOI: 10.1016/j.bpc.2011.05.011

Source DB:  PubMed          Journal:  Biophys Chem        ISSN: 0301-4622            Impact factor:   2.352


  44 in total

1.  Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity.

Authors:  M G Zagorski; J Yang; H Shao; K Ma; H Zeng; A Hong
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

Review 2.  Engineering amyloidogenicity towards the development of nanofibrillar materials.

Authors:  Daizo Hamada; Itaru Yanagihara; Kouhei Tsumoto
Journal:  Trends Biotechnol       Date:  2004-02       Impact factor: 19.536

Review 3.  The Hofmeister series: salt and solvent effects on interfacial phenomena.

Authors:  M G Cacace; E M Landau; J J Ramsden
Journal:  Q Rev Biophys       Date:  1997-08       Impact factor: 5.318

4.  Glycosaminoglycans in extracts of cardiac amyloid fibrils from familial amyloid cardiomyopathy of Danish origin related to variant transthyretin Met 111.

Authors:  J H Magnus; T Stenstad; S O Kolset; G Husby
Journal:  Scand J Immunol       Date:  1991-07       Impact factor: 3.487

5.  Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

Authors:  D M Hartley; D M Walsh; C P Ye; T Diehl; S Vasquez; P M Vassilev; D B Teplow; D J Selkoe
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

6.  The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis.

Authors:  J B Ancsin; R Kisilevsky
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

7.  Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen.

Authors:  H Ohishi; M Skinner; N Sato-Araki; T Okuyama; F Gejyo; A Kimura; A S Cohen; K Schmid
Journal:  Clin Chem       Date:  1990-01       Impact factor: 8.327

8.  Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells.

Authors:  S J Pollack; I I Sadler; S R Hawtin; V J Tailor; M S Shearman
Journal:  Neurosci Lett       Date:  1995-01-23       Impact factor: 3.046

9.  Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons.

Authors:  A G Woods; D H Cribbs; E R Whittemore; C W Cotman
Journal:  Brain Res       Date:  1995-10-30       Impact factor: 3.252

10.  The effect of macromolecular crowding on protein aggregation and amyloid fibril formation.

Authors:  Larissa A Munishkina; Elisa M Cooper; Vladimir N Uversky; Anthony L Fink
Journal:  J Mol Recognit       Date:  2004 Sep-Oct       Impact factor: 2.137

View more
  10 in total

1.  Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations.

Authors:  Luis M Blancas-Mejía; Alexander Tischer; James R Thompson; Jonathan Tai; Lin Wang; Matthew Auton; Marina Ramirez-Alvarado
Journal:  J Mol Biol       Date:  2013-10-22       Impact factor: 5.469

2.  Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.

Authors:  Luis M Blancas-Mejía; Jared Hammernik; Marta Marin-Argany; Marina Ramirez-Alvarado
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

3.  Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.

Authors:  Kathrin Andrich; Ute Hegenbart; Christoph Kimmich; Niraja Kedia; H Robert Bergen; Stefan Schönland; Erich Wanker; Jan Bieschke
Journal:  J Biol Chem       Date:  2016-12-28       Impact factor: 5.157

Review 4.  Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.

Authors:  Hidehiko Ikura; Jin Endo; Hiroki Kitakata; Hidenori Moriyama; Motoaki Sano; Keiichi Fukuda
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

Review 5.  Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.

Authors:  Omid Tavassoly; Farinaz Safavi; Iman Tavassoly
Journal:  Mol Pharmacol       Date:  2020-09-10       Impact factor: 4.436

Review 6.  Amyloid formation in light chain amyloidosis.

Authors:  Marina Ramirez-Alvarado
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

7.  Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A.

Authors:  J Javier Aguilera; Fuming Zhang; Julie M Beaudet; Robert J Linhardt; Wilfredo Colón
Journal:  Biochimie       Date:  2014-05-28       Impact factor: 4.079

Review 8.  Immunoglobulin light chain amyloid aggregation.

Authors:  Luis M Blancas-Mejia; Pinaki Misra; Christopher J Dick; Shawna A Cooper; Keely R Redhage; Michael R Bergman; Torri L Jordan; Khansaa Maar; Marina Ramirez-Alvarado
Journal:  Chem Commun (Camb)       Date:  2018-09-20       Impact factor: 6.222

Review 9.  Pathophysiology and treatment of systemic amyloidosis.

Authors:  Julian D Gillmore; Philip N Hawkins
Journal:  Nat Rev Nephrol       Date:  2013-08-27       Impact factor: 28.314

10.  Heparan sulfates facilitate harmless amyloidogenic fibril formation interacting with elastin-like peptides.

Authors:  Federica Boraldi; Pasquale Moscarelli; Brigida Bochicchio; Antonietta Pepe; Anna M Salvi; Daniela Quaglino
Journal:  Sci Rep       Date:  2018-02-15       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.